➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Baxter
Express Scripts
Mallinckrodt
Johnson and Johnson

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

HUMIRA Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for HUMIRA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
St George's, University of LondonPhase 4
Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesPhase 4
Wake Forest University Health SciencesPhase 4

See all HUMIRA clinical trials

Recent Litigation for HUMIRA

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Coherus Biosciences, Inc. v. Amgen Inc.2019-01-24
ABBVIE INC. v. SANDOZ INC.2018-08-10
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06

See all HUMIRA litigation

PTAB Litigation
PetitionerDate
Fresenius Kabi USA, LLC2019-09-17
2017-12-20
Sandoz Inc.2017-11-06

See all HUMIRA litigation

Pharmacology for HUMIRA

Patent Text Search: US Patents for HUMIRA

These patents were identified by searching patent claims

Supplementary Protection Certificates for HUMIRA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
PA2016034 Lithuania   Start Trial PRODUCT NAME: IBRUTINIBAS ARBA FARMACISKAI PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 C(2016)3293 20160526
1790062-2 Sweden   Start Trial PRODUCT NAME: SARILUMAB; REG. NO/DATE: EU/1/17/1196 20170627
300728 Netherlands   Start Trial DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), SAMENVOEGEN
CA 2020 00011 Denmark   Start Trial PRODUCT NAME: UPADACITINIB; REG. NO/DATE: EU/1/19/1404 20191218
PA2015017 Lithuania   Start Trial PRODUCT NAME: IBRUTINIBUM; REGISTRATION NO/DATE: EU/1/14/945 20141021
132017000036530 Italy   Start Trial PRODUCT NAME: IBRUTINIB O SUO SALE FARMACEUTICAMENTE ACCETTABILE(IMBRUVICA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/4/945, 20150707
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Dow
AstraZeneca
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.